MET and medulloblastoma: First, MET gene amplification or copy number gain (CNG), leading to MET overexpression and its ligand-independent activation, has been identified as responsible for carcinogenesis in several tumour types including glioblastoma (Cancer Genome Atlas Research Network, 2023), lung adenocarcinoma (LUAD) (Collisson et al., 2014), gastric cancer (GC) (Asaoka et al., 2010), colorectal cancer (CRC) (Umeki et al., 1999), and medulloblastoma (Tong et al., 2004).